Search research articles
Contact Us
Filters
Showing results (151-160 of 157) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 157 results.
Breast Cancer Research : BCR
|
May 7, 2026
The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer
Sahil Seth, Clinton Yam, Lei Huo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2021
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Clinton Yam, Er-Yen Yen, Jeffrey T Chang, et al.
The Journal of Clinical Investigation
|
June 3, 2025
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models
Mei-Kuang Chen, Hirohito Yamaguchi, Yuan Gao, et al.
Journal for Immunotherapy of Cancer
|
March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Mary B Daly, Tuya Pal, Michael P Berry, et al.
Cancer Research Communications
|
October 2, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Clinton Yam, Miral Patel, Holly A Hill, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 157) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 157 results.
Breast Cancer Research : BCR
|
May 7, 2026
The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer
Sahil Seth, Clinton Yam, Lei Huo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2021
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Clinton Yam, Er-Yen Yen, Jeffrey T Chang, et al.
The Journal of Clinical Investigation
|
June 3, 2025
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models
Mei-Kuang Chen, Hirohito Yamaguchi, Yuan Gao, et al.
Journal for Immunotherapy of Cancer
|
March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Mary B Daly, Tuya Pal, Michael P Berry, et al.
Cancer Research Communications
|
October 2, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Clinton Yam, Miral Patel, Holly A Hill, et al.
Page
of 16